Summary of TEAEs in the ASPEN and LTE1 studies
| Patients with ≥1 TEAE, n (%) . | Patients from ASPEN study who transitioned to zanubrutinib (N = 47) . | |
|---|---|---|
| ASPEN: Ibrutinib . | LTE1: Zanubrutinib . | |
| TEAE | 47 (100) | 38 (80.9) |
| Treatment related | 42 (89.4) | 17 (36.2) |
| Serious | 22 (46.8) | 6 (12.8) |
| Treatment related | 15 (31.9) | 0 |
| Leading to treatment discontinuation | 3 (6.4) | 2 (4.3) |
| Leading to dose reduction | 11 (23.4) | 0 |
| Leading to dose interruption | 30 (63.8) | 11 (23.4) |
| Fatal TEAE | NA | 2 (4.3) |
| Patients with ≥1 TEAE, n (%) . | Patients from ASPEN study who transitioned to zanubrutinib (N = 47) . | |
|---|---|---|
| ASPEN: Ibrutinib . | LTE1: Zanubrutinib . | |
| TEAE | 47 (100) | 38 (80.9) |
| Treatment related | 42 (89.4) | 17 (36.2) |
| Serious | 22 (46.8) | 6 (12.8) |
| Treatment related | 15 (31.9) | 0 |
| Leading to treatment discontinuation | 3 (6.4) | 2 (4.3) |
| Leading to dose reduction | 11 (23.4) | 0 |
| Leading to dose interruption | 30 (63.8) | 11 (23.4) |
| Fatal TEAE | NA | 2 (4.3) |
NA, not applicable.